Absence of HIV-1 evolution in the gut-associated lymphoid tissue from patients on combination antiviral therapy initiated during primary infection

Teresa H Evering, Saurabh Mehandru, Paul Racz, Klara Tenner-Racz, Michael A Poles, Amir Figueroa, Hiroshi Mohri, Martin Markowitz, Teresa H Evering, Saurabh Mehandru, Paul Racz, Klara Tenner-Racz, Michael A Poles, Amir Figueroa, Hiroshi Mohri, Martin Markowitz

Abstract

Mucosal mononuclear (MMC) CCR5+CD4+ T cells of the gastrointestinal (GI) tract are selectively infected and depleted during acute HIV-1 infection. Despite early initiation of combination antiretroviral therapy (cART), gut-associated lymphoid tissue (GALT) CD4+ T cell depletion and activation persist in the majority of HIV-1 positive individuals studied. This may result from ongoing HIV-1 replication and T-cell activation despite effective cART. We hypothesized that ongoing viral replication in the GI tract during cART would result in measurable viral evolution, with divergent populations emerging over time. Subjects treated during early HIV-1 infection underwent phlebotomy and flexible sigmoidoscopy with biopsies prior to and 15-24 months post initiation of cART. At the 2(nd) biopsy, three GALT phenotypes were noted, characterized by high, intermediate and low levels of immune activation. A representative case from each phenotype was analyzed. Each subject had plasma HIV-1 RNA levels <50 copies/ml at 2(nd) GI biopsy and CD4+ T cell reconstitution in the peripheral blood. Single genome amplification of full-length HIV-1 envelope was performed for each subject pre- and post-initiation of cART in GALT and PBMC. A total of 280 confirmed single genome sequences (SGS) were analyzed for experimental cases. For each subject, maximum likelihood phylogenetic trees derived from molecular sequence data showed no evidence of evolved forms in the GALT over the study period. During treatment, HIV-1 envelope diversity in GALT-derived SGS did not increase and post-treatment GALT-derived SGS showed no substantial genetic divergence from pre-treatment sequences within transmitted groups. Similar results were obtained from PBMC-derived SGS. Our results reveal that initiation of cART during acute/early HIV-1 infection can result in the interruption of measurable viral evolution in the GALT, suggesting the absence of de-novo rounds of HIV-1 replication in this compartment during suppressive cART.

Conflict of interest statement

MM serves as a paid consultant for Gilead, Tibotec, Merck and ViiV Healthcare/GlaxoSmithKline. He is also a paid speaker for Gilead and Tibotec and receives Research Support from Gilead. The remaining authors have declared that no competing interests exist.

Figures

Figure 1. Immunological profiles of experimental patients…
Figure 1. Immunological profiles of experimental patients before and after initiation of cART.
(A) Representative flow plots from low immune activator patient (LIA) are depicted. CD8+ T cells are shown on the x-axis and CD4+ T cells on the y-axis. (B, C) Bar graphs depicting CD4∶CD8 ratio (B) and levels of immune activation (C) of PBMC (red bars) and MMC (blue bars) before (PBMC1 and MMC1) and after (PBMC2 and MMC2) initiation of antiretroviral therapy. High immune activator (HIA), intermediate immune activator (IIA) and low immune activator (LIA) are compared. (D, E) Immunohistochemical characterization of immune effector sites in rectosigmoid biopsies. Using a PC-based image-analysis system (KS 4000, Kontron) a standard area was set by the image analyzer. A total of between 10 and 15 consecutive non-overlapping fields were analyzed. In figure (D), a biopsy section (viewed at 40× magnification) compares CD4+ T cells (stained red) of subject IIA before (left panel) and after (right panel) initiation of antiretroviral therapy. Figure (E) depicts mean CD4+ T before (LP1) and after (LP2) initiation of antiretroviral therapy. HIA, IIA and LIA are compared.
Figure 2. Intra-Patient clustering of HIV-1 env…
Figure 2. Intra-Patient clustering of HIV-1 env quasi-species.
Maximum Likelihood (ML) tree depicting full-length HIV-1 env sequences from three experimental subjects (HIA, IIA, LIA) and 2 positive control subjects (POS1 and POS2). For each subject, all sequences from both time-points (baseline and on treatment) and from all compartments described are shown. Bootstrap values (>95%) are shown for inter-subject clusters. 1000 bootstrap replicates were run and Bootstrap values over 85% are shown. The horizontal scale bar represents 2.0% genetic distance. Each subject forms a tight cluster and is distinct from other experimental subjects or controls. HXB2 was used as an outgroup.
Figure 3. Evolution of HIV-1 env in…
Figure 3. Evolution of HIV-1 env in the absence of cART – positive control patients.
ML tree of SGA sequences from (A) positive control subject 1 (POS1) and (B) positive control subject 2 (POS2). For both panels, PBMC time point #1 (open red circles) and PBMC time point #2 (closed red circles) are shown. 1000 bootstrap replicates were run and Bootstrap values over 85% are shown. The scale bar represents 0.005 nucleotide substitutions per site. HXB2 was used as an outgroup. Starred sequences represent those determined to be hypermutated. On the right is a Highlighter plot corresponding to the ML tree (outgroup sequence not shown). Individual nucleotide changes from a master sequence (TP1 sequence at the top of the ML tree) are shown. A-green; T-red; G-orange; C-light blue. For participant POS2, phylogenetic analysis reveals acquisition of more than one variant as shown.
Figure 4. HIV-1 env phylogenies do not…
Figure 4. HIV-1 env phylogenies do not suggest measurable evolution on suppressive cART.
ML tree of SGA sequences from participants (A) HIA (B) IIA and (C) LIA. For all panels, PBMC time point #1 (open red circles), PBMC time point #2 (closed red circles), GALT time point #1 (open blue squares) and GALT time point #2 (closed blue squares) are shown. 1000 bootstrap replicates were run and Bootstrap values over 85% are shown. The scale bar represents 0.005 nucleotide substitutions per site. HXB2 was used as an outgroup. Starred sequences represent those determined to be hypermutated. To the right of each ML tree is the corresponding Highlighter plot (outgroup sequence not shown). Individual nucleotide changes from a master sequence (TP1 sequence at the top of the ML tree) are shown. A-green; T-red; G-orange; C-light blue. For participant IIA, phylogenetic analysis reveals acquisition of more than one variant with in-vivo inter-lineage recombinants. Sequences surrounded by boxes represent HIV-1 env recombinants (red boxes denote a sequence p value of p<0.05 in Recco; black boxes denote a sequence p value of p<0.25 in Recco).

References

    1. Mellors JW, Rinaldo CR, Jr, Gupta P, White RM, Todd JA, et al. Prognosis in HIV-1 infection predicted by the quantity of virus in plasma. Science. 1996;272:1167–1170.
    1. Daar ES. Virology and immunology of acute HIV type 1 infection. AIDS Res Hum Retroviruses. 1998;14(Suppl 3):S229–234.
    1. Rosenberg ES, Altfeld M, Poon SH, Phillips MN, Wilkes BM, et al. Immune control of HIV-1 after early treatment of acute infection. Nature. 2000;407:523–526.
    1. Mohri H, Perelson AS, Tung K, Ribeiro RM, Ramratnam B, et al. Increased turnover of T lymphocytes in HIV-1 infection and its reduction by antiretroviral therapy. J Exp Med. 2001;194:1277–1287.
    1. Chun TW, Carruth L, Finzi D, Shen X, DiGiuseppe JA, et al. Quantification of latent tissue reservoirs and total body viral load in HIV-1 infection. Nature. 1997;387:183–188.
    1. CDC. Epidemiology of HIV/AIDS–United States, 1981–2005. MMWR Morb Mortal Wkly Rep. 2006;55:589–592.
    1. Palella FJ, Jr, Delaney KM, Moorman AC, Loveless MO, Fuhrer J, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med. 1998;338:853–860.
    1. Zhang ZQ, Notermans DW, Sedgewick G, Cavert W, Wietgrefe S, et al. Kinetics of CD4+ T cell repopulation of lymphoid tissues after treatment of HIV-1 infection. Proc Natl Acad Sci U S A. 1998;95:1154–1159.
    1. Autran B, Carcelain G, Li TS, Blanc C, Mathez D, et al. Positive effects of combined antiretroviral therapy on CD4+ T cell homeostasis and function in advanced HIV disease. Science. 1997;277:112–116.
    1. Pakker NG, Notermans DW, de Boer RJ, Roos MT, de Wolf F, et al. Biphasic kinetics of peripheral blood T cells after triple combination therapy in HIV-1 infection: a composite of redistribution and proliferation. Nat Med. 1998;4:208–214.
    1. Wong JK, Gunthard HF, Havlir DV, Zhang ZQ, Haase AT, et al. Reduction of HIV-1 in blood and lymph nodes following potent antiretroviral therapy and the virologic correlates of treatment failure. Proc Natl Acad Sci U S A. 1997;94:12574–12579.
    1. Finzi D, Hermankova M, Pierson T, Carruth LM, Buck C, et al. Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. Science. 1997;278:1295–1300.
    1. Wong JK, Hezareh M, Gunthard HF, Havlir DV, Ignacio CC, et al. Recovery of replication-competent HIV despite prolonged suppression of plasma viremia. Science. 1997;278:1291–1295.
    1. Volberding PA, Deeks SG. Antiretroviral therapy for HIV infection: promises and problems. JAMA. 1998;279:1343–1344.
    1. Markowitz M, Jin X, Hurley A, Simon V, Ramratnam B, et al. Discontinuation of antiretroviral therapy commenced early during the course of human immunodeficiency virus type 1 infection, with or without adjunctive vaccination. J Infect Dis. 2002;186:634–643.
    1. Finzi D, Blankson J, Siliciano JD, Margolick JB, Chadwick K, et al. Latent infection of CD4+ T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy. Nat Med. 1999;5:512–517.
    1. Chun TW, Engel D, Mizell SB, Ehler LA, Fauci AS. Induction of HIV-1 replication in latently infected CD4+ T cells using a combination of cytokines. J Exp Med. 1998;188:83–91.
    1. Mowat AM. Anatomical basis of tolerance and immunity to intestinal antigens. Nat Rev Immunol. 2003;3:331–341.
    1. Kim SK, Reed DS, Heath WR, Carbone F, Lefrancois L. Activation and migration of CD8 T cells in the intestinal mucosa. J Immunol. 1997;159:4295–4306.
    1. Schieferdecker HL, Ullrich R, Hirseland H, Zeitz M. T cell differentiation antigens on lymphocytes in the human intestinal lamina propria. J Immunol. 1992;149:2816–2822.
    1. Veazey RS, DeMaria M, Chalifoux LV, Shvetz DE, Pauley DR, et al. Gastrointestinal tract as a major site of CD4+ T cell depletion and viral replication in SIV infection. Science. 1998;280:427–431.
    1. Smit-McBride Z, Mattapallil JJ, McChesney M, Ferrick D, Dandekar S. Gastrointestinal T lymphocytes retain high potential for cytokine responses but have severe CD4(+) T-cell depletion at all stages of simian immunodeficiency virus infection compared to peripheral lymphocytes. J Virol. 1998;72:6646–6656.
    1. Harouse JM, Gettie A, Tan RC, Blanchard J, Cheng-Mayer C. Distinct pathogenic sequela in rhesus macaques infected with CCR5 or CXCR4 utilizing SHIVs. Science. 1999;284:816–819.
    1. Mattapallil JJ, Douek DC, Hill B, Nishimura Y, Martin M, et al. Massive infection and loss of memory CD4+ T cells in multiple tissues during acute SIV infection. Nature. 2005;434:1093–1097.
    1. Veazey RS, Mansfield KG, Tham IC, Carville AC, Shvetz DE, et al. Dynamics of CCR5 expression by CD4(+) T cells in lymphoid tissues during simian immunodeficiency virus infection. J Virol. 2000;74:11001–11007.
    1. Nabel G, Baltimore D. An inducible transcription factor activates expression of human immunodeficiency virus in T cells. Nature. 1987;326:711–713.
    1. Poles MA, Elliott J, Taing P, Anton PA, Chen IS. A preponderance of CCR5(+) CXCR4(+) mononuclear cells enhances gastrointestinal mucosal susceptibility to human immunodeficiency virus type 1 infection. J Virol. 2001;75:8390–8399.
    1. Anton PA, Elliott J, Poles MA, McGowan IM, Matud J, et al. Enhanced levels of functional HIV-1 co-receptors on human mucosal T cells demonstrated using intestinal biopsy tissue. AIDS. 2000;14:1761–1765.
    1. Brenchley JM, Schacker TW, Ruff LE, Price DA, Taylor JH, et al. CD4+ T cell depletion during all stages of HIV disease occurs predominantly in the gastrointestinal tract. J Exp Med. 2004;200:749–759.
    1. Mehandru S, Poles MA, Tenner-Racz K, Horowitz A, Hurley A, et al. Primary HIV-1 infection is associated with preferential depletion of CD4+ T lymphocytes from effector sites in the gastrointestinal tract. J Exp Med. 2004;200:761–770.
    1. Guadalupe M, Reay E, Sankaran S, Prindiville T, Flamm J, et al. Severe CD4+ T-cell depletion in gut lymphoid tissue during primary human immunodeficiency virus type 1 infection and substantial delay in restoration following highly active antiretroviral therapy. J Virol. 2003;77:11708–11717.
    1. Mehandru S, Poles MA, Tenner-Racz K, Jean-Pierre P, Manuelli V, et al. Lack of mucosal immune reconstitution during prolonged treatment of acute and early HIV-1 infection. PLoS Med. 2006;3:e484.
    1. Mehandru S, Poles MA, Tenner-Racz K, Manuelli V, Jean-Pierre P, et al. Mechanisms of gastrointestinal CD4+ T-cell depletion during acute and early human immunodeficiency virus type 1 infection. J Virol. 2007;81:599–612.
    1. Chun TW, Engel D, Berrey MM, Shea T, Corey L, et al. Early establishment of a pool of latently infected, resting CD4(+) T cells during primary HIV-1 infection. Proc Natl Acad Sci U S A. 1998;95:8869–8873.
    1. Palmer S, Wiegand AP, Maldarelli F, Bazmi H, Mican JM, et al. New real-time reverse transcriptase-initiated PCR assay with single-copy sensitivity for human immunodeficiency virus type 1 RNA in plasma. J Clin Microbiol. 2003;41:4531–4536.
    1. Ramratnam B, Ribeiro R, He T, Chung C, Simon V, et al. Intensification of antiretroviral therapy accelerates the decay of the HIV-1 latent reservoir and decreases, but does not eliminate, ongoing virus replication. J Acquir Immune Defic Syndr. 2004;35:33–37.
    1. Lewin SR, Vesanen M, Kostrikis L, Hurley A, Duran M, et al. Use of real-time PCR and molecular beacons to detect virus replication in human immunodeficiency virus type 1-infected individuals on prolonged effective antiretroviral therapy. J Virol. 1999;73:6099–6103.
    1. Chun TW, Nickle DC, Justement JS, Large D, Semerjian A, et al. HIV-infected individuals receiving effective antiviral therapy for extended periods of time continually replenish their viral reservoir. J Clin Invest. 2005;115:3250–3255.
    1. Sharkey ME, Teo I, Greenough T, Sharova N, Luzuriaga K, et al. Persistence of episomal HIV-1 infection intermediates in patients on highly active anti-retroviral therapy. Nat Med. 2000;6:76–81.
    1. Zhang L, Ramratnam B, Tenner-Racz K, He Y, Vesanen M, et al. Quantifying residual HIV-1 replication in patients receiving combination antiretroviral therapy. N Engl J Med. 1999;340:1605–1613.
    1. Buzon MJ, Massanella M, Llibre JM, Esteve A, Dahl V, et al. HIV-1 replication and immune dynamics are affected by raltegravir intensification of HAART-suppressed subjects. Nat Med. 2010;16:460–465.
    1. Benito JM, Lopez M, Lozano S, Martinez P, Gonzalez-Lahoz J, et al. CD38 expression on CD8 T lymphocytes as a marker of residual virus replication in chronically HIV-infected patients receiving antiretroviral therapy. AIDS Res Hum Retroviruses. 2004;20:227–233.
    1. Gunthard HF, Wong JK, Ignacio CC, Guatelli JC, Riggs NL, et al. Human immunodeficiency virus replication and genotypic resistance in blood and lymph nodes after a year of potent antiretroviral therapy. J Virol. 1998;72:2422–2428.
    1. Martinez MA, Cabana M, Ibanez A, Clotet B, Arno A, et al. Human immunodeficiency virus type 1 genetic evolution in patients with prolonged suppression of plasma viremia. Virology. 1999;256:180–187.
    1. Shiu C, Cunningham CK, Greenough T, Muresan P, Sanchez-Merino V, et al. Identification of ongoing human immunodeficiency virus type 1 (HIV-1) replication in residual viremia during recombinant HIV-1 poxvirus immunizations in patients with clinically undetectable viral loads on durable suppressive highly active antiretroviral therapy. J Virol. 2009;83:9731–9742.
    1. Gunthard HF, Frost SD, Leigh-Brown AJ, Ignacio CC, Kee K, et al. Evolution of envelope sequences of human immunodeficiency virus type 1 in cellular reservoirs in the setting of potent antiviral therapy. J Virol. 1999;73:9404–9412.
    1. Bailey JR, Sedaghat AR, Kieffer T, Brennan T, Lee PK, et al. Residual human immunodeficiency virus type 1 viremia in some patients on antiretroviral therapy is dominated by a small number of invariant clones rarely found in circulating CD4+ T cells. J Virol. 2006;80:6441–6457.
    1. Dinoso JB, Kim SY, Wiegand AM, Palmer SE, Gange SJ, et al. Treatment intensification does not reduce residual HIV-1 viremia in patients on highly active antiretroviral therapy. Proc Natl Acad Sci U S A. 2009;106:9403–9408.
    1. Kieffer TL, Finucane MM, Nettles RE, Quinn TC, Broman KW, et al. Genotypic analysis of HIV-1 drug resistance at the limit of detection: virus production without evolution in treated adults with undetectable HIV loads. J Infect Dis. 2004;189:1452–1465.
    1. Shen L, Siliciano RF. Viral reservoirs, residual viremia, and the potential of highly active antiretroviral therapy to eradicate HIV infection. J Allergy Clin Immunol. 2008;122:22–28.
    1. Sedaghat AR, Siliciano JD, Brennan TP, Wilke CO, Siliciano RF. Limits on replenishment of the resting CD4+ T cell reservoir for HIV in patients on HAART. PLoS Pathog. 2007;3:e122.
    1. Sedaghat AR, Siliciano RF, Wilke CO. Low-level HIV-1 replication and the dynamics of the resting CD4+ T cell reservoir for HIV-1 in the setting of HAART. BMC Infect Dis. 2008;8:2.
    1. Joos B, Fischer M, Kuster H, Pillai SK, Wong JK, et al. HIV rebounds from latently infected cells, rather than from continuing low-level replication. Proc Natl Acad Sci U S A. 2008;105:16725–16730.
    1. Sigal A, Kim JT, Balazs AB, Dekel E, Mayo A, et al. Cell-to-cell spread of HIV permits ongoing replication despite antiretroviral therapy. Nature. 2011;477:95–98.
    1. Palmer S, Kearney M, Maldarelli F, Halvas EK, Bixby CJ, et al. Multiple, linked human immunodeficiency virus type 1 drug resistance mutations in treatment-experienced patients are missed by standard genotype analysis. J Clin Microbiol. 2005;43:406–413.
    1. Shriner D, Rodrigo AG, Nickle DC, Mullins JI. Pervasive genomic recombination of HIV-1 in vivo. Genetics. 2004;167:1573–1583.
    1. Simmonds P, Balfe P, Ludlam CA, Bishop JO, Brown AJ. Analysis of sequence diversity in hypervariable regions of the external glycoprotein of human immunodeficiency virus type 1. J Virol. 1990;64:5840–5850.
    1. Simmonds P, Balfe P, Peutherer JF, Ludlam CA, Bishop JO, et al. Human immunodeficiency virus-infected individuals contain provirus in small numbers of peripheral mononuclear cells and at low copy numbers. J Virol. 1990;64:864–872.
    1. Butler DM, Pacold ME, Jordan PS, Richman DD, Smith DM. The efficiency of single genome amplification and sequencing is improved by quantitation and use of a bioinformatics tool. J Virol Methods. 2009;162:280–283.
    1. Fang G, Zhu G, Burger H, Keithly JS, Weiser B. Minimizing DNA recombination during long RT-PCR. J Virol Methods. 1998;76:139–148.
    1. Meyerhans A, Vartanian JP, Wain-Hobson S. DNA recombination during PCR. Nucleic Acids Res. 1990;18:1687–1691.
    1. Yang YL, Wang G, Dorman K, Kaplan AH. Long polymerase chain reaction amplification of heterogeneous HIV type 1 templates produces recombination at a relatively high frequency. AIDS Res Hum Retroviruses. 1996;12:303–306.
    1. Salazar-Gonzalez JF, Bailes E, Pham KT, Salazar MG, Guffey MB, et al. Deciphering human immunodeficiency virus type 1 transmission and early envelope diversification by single-genome amplification and sequencing. J Virol. 2008;82:3952–3970.
    1. Hazenberg MD, Otto SA, van Benthem BH, Roos MT, Coutinho RA, et al. Persistent immune activation in HIV-1 infection is associated with progression to AIDS. AIDS. 2003;17:1881–1888.
    1. Salazar-Gonzalez J, Pham K, Keele B, McPherson D. Standard Operating Procedure for: Single Genome Amplification of HIV-1 Envelope [SOP#: CHAVI-MBSC-1]. University of Alabama at Birmingham 2007
    1. Learn GH, Jr, Korber BT, Foley B, Hahn BH, Wolinsky SM, et al. Maintaining the integrity of human immunodeficiency virus sequence databases. J Virol. 1996;70:5720–5730.
    1. Alcantara LC, Cassol S, Libin P, Deforche K, Pybus OG, et al. A standardized framework for accurate, high-throughput genotyping of recombinant and non-recombinant viral sequences. Nucleic Acids Res. 2009;37:W634–642.
    1. de Oliveira T, Deforche K, Cassol S, Salminen M, Paraskevis D, et al. An automated genotyping system for analysis of HIV-1 and other microbial sequences. Bioinformatics. 2005;21:3797–3800.
    1. Choe H, Farzan M, Sun Y, Sullivan N, Rollins B, et al. The beta-chemokine receptors CCR3 and CCR5 facilitate infection by primary HIV-1 isolates. Cell. 1996;85:1135–1148.
    1. Connor RI, Sheridan KE, Ceradini D, Choe S, Landau NR. Change in coreceptor use correlates with disease progression in HIV-1–infected individuals. J Exp Med. 1997;185:621–628.
    1. Brumme ZL, Dong WW, Yip B, Wynhoven B, Hoffman NG, et al. Clinical and immunological impact of HIV envelope V3 sequence variation after starting initial triple antiretroviral therapy. AIDS. 2004;18:F1–9.
    1. Jensen MA, Li FS, van't Wout AB, Nickle DC, Shriner D, et al. Improved coreceptor usage prediction and genotypic monitoring of R5-to-X4 transition by motif analysis of human immunodeficiency virus type 1 env V3 loop sequences. J Virol. 2003;77:13376–13388.
    1. Richman DD, Bozzette SA. The impact of the syncytium-inducing phenotype of human immunodeficiency virus on disease progression. J Infect Dis. 1994;169:968–974.
    1. Moore JP, Kitchen SG, Pugach P, Zack JA. The CCR5 and CXCR4 coreceptors–central to understanding the transmission and pathogenesis of human immunodeficiency virus type 1 infection. AIDS Res Hum Retroviruses. 2004;20:111–126.
    1. Margolis L, Shattock R. Selective transmission of CCR5-utilizing HIV-1: the ‘gatekeeper’ problem resolved? Nat Rev Microbiol. 2006;4:312–317.
    1. Whitcomb JM, Huang W, Fransen S, Limoli K, Toma J, et al. Development and characterization of a novel single-cycle recombinant-virus assay to determine human immunodeficiency virus type 1 coreceptor tropism. Antimicrob Agents Chemother. 2007;51:566–575.
    1. Keele BF, Giorgi EE, Salazar-Gonzalez JF, Decker JM, Pham KT, et al. Identification and characterization of transmitted and early founder virus envelopes in primary HIV-1 infection. Proc Natl Acad Sci U S A. 2008;105:7552–7557.
    1. Tamura K, Dudley J, Nei M, Kumar S. MEGA4: Molecular Evolutionary Genetics Analysis (MEGA) software version 4.0. Mol Biol Evol. 2007;24:1596–1599.
    1. Rose PP, Korber BT. Detecting hypermutations in viral sequences with an emphasis on G→A hypermutation. Bioinformatics. 2000;16:400–401.
    1. Vartanian JP, Meyerhans A, Sala M, Wain-Hobson S. G→A hypermutation of the human immunodeficiency virus type 1 genome: evidence for dCTP pool imbalance during reverse transcription. Proc Natl Acad Sci U S A. 1994;91:3092–3096.
    1. Martinez MA, Vartanian JP, Wain-Hobson S. Hypermutagenesis of RNA using human immunodeficiency virus type 1 reverse transcriptase and biased dNTP concentrations. Proc Natl Acad Sci U S A. 1994;91:11787–11791.
    1. Li H, Bar KJ, Wang S, Decker JM, Chen Y, et al. High Multiplicity Infection by HIV-1 in Men Who Have Sex with Men. PLoS Pathog. 2010;6:e1000890.
    1. Shankarappa R, Margolick JB, Gange SJ, Rodrigo AG, Upchurch D, et al. Consistent viral evolutionary changes associated with the progression of human immunodeficiency virus type 1 infection. J Virol. 1999;73:10489–10502.
    1. Saitou N, Nei M. The neighbor-joining method: a new method for reconstructing phylogenetic trees. Mol Biol Evol. 1987;4:406–425.
    1. Ronquist F, Huelsenbeck JP. MrBayes 3: Bayesian phylogenetic inference under mixed models. Bioinformatics. 2003;19:1572–1574.
    1. Hudson RR, Kaplan NL. Statistical properties of the number of recombination events in the history of a sample of DNA sequences. Genetics. 1985;111:147–164.
    1. Rozas J, Sanchez-DelBarrio JC, Messeguer X, Rozas R. DnaSP, DNA polymorphism analyses by the coalescent and other methods. Bioinformatics. 2003;19:2496–2497.
    1. Maydt J, Lengauer T. Recco: recombination analysis using cost optimization. Bioinformatics. 2006;22:1064–1071.
    1. Mens H, Kearney M, Wiegand A, Shao W, Schonning K, et al. HIV-1 continues to replicate and evolve in patients with natural control of HIV infection. J Virol. 2010;84:12971–12981.
    1. Achaz G, Palmer S, Kearney M, Maldarelli F, Mellors JW, et al. A robust measure of HIV-1 population turnover within chronically infected individuals. Mol Biol Evol. 2004;21:1902–1912.
    1. Hudson RR, Boos DD, Kaplan NL. A statistical test for detecting geographic subdivision. Mol Biol Evol. 1992;9:138–151.
    1. Kearney M, Spindler J, Shao W, Maldarelli F, Palmer S, et al. Genetic diversity of simian immunodeficiency virus encoding HIV-1 reverse transcriptase persists in macaques despite antiretroviral therapy. J Virol. 2011;85:1067–1076.
    1. Slatkin M, Maddison WP. A cladistic measure of gene flow inferred from the phylogenies of alleles. Genetics. 1989;123:603–613.
    1. Pond SL, Frost SD, Muse SV. HyPhy: hypothesis testing using phylogenies. Bioinformatics. 2005;21:676–679.
    1. Gantt S, Carlsson J, Heath L, Bull ME, Shetty AK, et al. Genetic analyses of HIV-1 env sequences demonstrate limited compartmentalization in breast milk and suggest viral replication within the breast that increases with mastitis. J Virol. 2010;84:10812–10819.
    1. Heath L, Fox A, McClure J, Diem K, van't Wout AB, et al. Evidence for limited genetic compartmentalization of HIV-1 between lung and blood. PLoS One. 2009;4:e6949.
    1. Bull M, Learn G, Genowati I, McKernan J, Hitti J, et al. Compartmentalization of HIV-1 within the female genital tract is due to monotypic and low-diversity variants not distinct viral populations. PLoS One. 2009;4:e7122.
    1. Bull ME, Learn GH, McElhone S, Hitti J, Lockhart D, et al. Monotypic human immunodeficiency virus type 1 genotypes across the uterine cervix and in blood suggest proliferation of cells with provirus. J Virol. 2009;83:6020–6028.
    1. Hatano H, Hayes TL, Dahl V, Sinclair E, Lee TH, et al. A randomized, controlled trial of raltegravir intensification in antiretroviral-treated, HIV-infected patients with a suboptimal CD4+ T cell response. J Infect Dis. 2011;203:960–968.
    1. Gandhi RT, Zheng L, Bosch RJ, Chan ES, Margolis DM, et al. The effect of raltegravir intensification on low-level residual viremia in HIV-infected patients on antiretroviral therapy: a randomized controlled trial. PLoS Med. 2010;7:pii: e1000321.
    1. Yukl SA, Shergill AK, McQuaid K, Gianella S, Lampiris H, et al. Effect of raltegravir-containing intensification on HIV burden and T-cell activation in multiple gut sites of HIV-positive adults on suppressive antiretroviral therapy. AIDS. 2010;24:2451–2460.
    1. Imamichi H, Degray G, Dewar RL, Mannon P, Yao M, et al. Lack of compartmentalization of HIV-1 quasispecies between the gut and peripheral blood compartments. J Infect Dis. 2011;204:309–314.
    1. Lerner P, Guadalupe M, Donovan R, Hung J, Flamm J, et al. Gut mucosal viral reservoir in HIV infected patients is not the major source of rebound plasma viremia following HAART interruption. J Virol. 2011;85:4772–4782.
    1. Anderson JA, Archin NM, Ince W, Parker D, Wiegand A, et al. Clonal Sequences Recovered From Residual HIV-1 Viremia In Patients On Intensified Antiretroviral Therapy Are Identical To Replicating Viral RNAs Recovered From Circulating Resting CD4+ T Cells. J Virol. 2011;85:5220–5223.
    1. McMahon D, Jones J, Wiegand A, Gange SJ, Kearney M, et al. Short-course raltegravir intensification does not reduce persistent low-level viremia in patients with HIV-1 suppression during receipt of combination antiretroviral therapy. Clin Infect Dis. 2010;50:912–919.
    1. Siliciano RF. Scientific rationale for antiretroviral therapy in 2005: viral reservoirs and resistance evolution. Top HIV Med. 2005;13:96–100.
    1. Fiebig EW, Wright DJ, Rawal BD, Garrett PE, Schumacher RT, et al. Dynamics of HIV viremia and antibody seroconversion in plasma donors: implications for diagnosis and staging of primary HIV infection. AIDS. 2003;17:1871–1879.
    1. Salazar-Gonzalez JF, Pham KT, Keele BF, McPherson D. Standard Operating Procedure for: Single Genome Amplification of HIV-1 Envelope [SOP#: CHAVI-MBSC-1]. University of Alabama at Birmingham 2007
    1. Huang X, Madan A. CAP3: A DNA sequence assembly program. Genome Res. 1999;9:868–877.
    1. Larkin MA, Blackshields G, Brown NP, Chenna R, McGettigan PA, et al. Clustal W and Clustal X version 2.0. Bioinformatics. 2007;23:2947–2948.
    1. Tamura K, Nei M. Estimation of the number of nucleotide substitutions in the control region of mitochondrial DNA in humans and chimpanzees. Mol Biol Evol. 1993;10:512–526.
    1. Guindon S, Gascuel O. A simple, fast, and accurate algorithm to estimate large phylogenies by maximum likelihood. Syst Biol. 2003;52:696–704.

Source: PubMed

赞助者和合作者

医疗条件

药物干预

3
订阅